Webinar: Modeling cardiac pathologies with TrueCardium™ | REPROCELL

Modeling cardiac pathologies with TrueCardium™: Engineered human tissue for drug discovery and cardiotoxicity screening

Generation of synthetic human tissue necessitates mimicry of native tissue cell composition, architecture, and molecular fidelity. Here, we detail the establishment of engineered iPSC-derived self-organized cardiac organoids (TrueCardium™ SCOs) comprising all cell types of native human cardiac tissue with its concordant molecular, metabolic, structural, and physiologic characteristics. SCO growth and maturation can be controlled and developmentally-staged to heart tissue from the linear heart stage to adult maturation. SCOs contain a lumen within the organoid core, enveloped by the putative endocardium, myocardium, and epicardium at the periphery. Further, TrueCardium™ SCOs exhibit vascularization characterized by 3D endothelial cell networks enveloped by mural cells, indicative of vessel stability and maturation and extensive intratissue neurogenesis. With this TrueCardium™ platform, we can for the first time model the morphologic, physiologic, and functional impact of a broad spectrum of cardiac indications, ranging from congenital Rare disease neuromusculopathies, to stress-induced cardiac pathologies and cardioinflammatory disease.

https://www.reprocell.com/
____________________________________________________________________________
Follow us on LinkedIn:   / reprocell  
Follow us on Twitter:   / reprocellglobal  
____________________________________________________________________________
Browse our product catalog: https://www.reprocell.com/product-cat...
Got a research project you are looking to outsource? Contact our scientists to arrange a free consultation: https://www.reprocell.com/contact